Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > legal

: Currently legal in most jurisdictions with thujone limits

or Rx

or Rx-only in US

Use the filters below to narrow your results.

None (11) · Artemisia absinthium (1) · Avanafil (1) · Bisoprolol (1) · Memantine ER / Donepezil (1) · Metoprolol (1) · Nebivolol (1) · Prazosin (1) · Propranolol (1) · Sertraline (1) · Sildenafil (1) · Tadalafil (1) · Vardenafil (1)

5HT1A activity than aripiprazole (1) · 5HT2A (1) · 5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity (1) · Alpha-1 Adrenergic Antagonist (1) · Anti-CGRP ligand monoclonal antibody (3) · Anti-CGRP receptor monoclonal antibody (1) · Antidepressant (1) · Anxiolytic (1) · Atypical antipsychotic (3) · Beta Blocker (4) · Cardioselective (β1) (2) · Cardioselective (β1) + vasodilator (1) · CGRP receptor antagonist (1) · Combined cholinesterase inhibitor + NMDA antagonist (1) · D2/5HT1A partial agonist with stronger α1A (1) · D2/D3/5HT1A partial agonist (1) · Gepant (1) · Multimodal antidepressant: SERT inhibitor + 5HT1A agonist + 5HT1B partial agonist + 5HT3/5HT7 antagonist (1) · NMDA receptor antagonist + sigma-1 agonist + NDRI (combination) (1) · Non-selective (1) · PDE5 Inhibitor (4) · Plant Medicine (1) · Rhapsodica (1) · Serotonin partial agonist reuptake inhibitor (SPARI) (1) · SSRI (1)

None (5) · Active principle is thujone, a GABA-A antagonist (the opposite of most CNS depressants). Also present in cooking sage (''Salvia officinalis''), tansy, and ''Thuja'' cedars. (1) · Cardioselective β1-adrenergic antagonist. Selectivity is dose-dependent and partially lost at higher doses. (1) · Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · Non-selective competitive antagonist at β1 and β2 adrenergic receptors. Lipophilic; significant blood–brain barrier penetration, accounting for its CNS effects. (1) · Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) · Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares. (1) · Selective inhibitor of PDE5 with a substantially longer half-life than other PDE5 inhibitors, allowing once-daily continuous dosing. (1) · Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation. (1) · Small-molecule CGRP receptor antagonist; intranasal formulation (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1)

1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) (1) · 1 tablet (dextromethorphan 45 mg / bupropion 105 mg) PO daily × 3 days, then increase to 1 tablet BID (1) · 10 mg (one spray) intranasally in one nostril (1) · 10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food) (1) · 10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed (1) · 10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH (1) · 10 mg ~1 h before sexual activity (1) · 100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) · 100 mg ~15 min before sexual activity (1) · 10–40 mg (situational anxiety); 40 mg BID (HTN) (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 25 mg (1) · 25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) · 42 mg PO once daily with food (no titration) (1) · 5 mg daily (1) · 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) · 70 mg SC monthly; may increase to 140 mg monthly (1) · A measured pour of absinthe diluted 5:1 with cold water over sugar (the louche ritual) (1) · For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) · Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)

0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · 1, 2, 5 mg caps (1) · 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) · 10 mg, 20 mg, 40 mg tablets (1) · 10 mg/spray nasal solution (1) · 10, 20, 40, 60, 80 mg tabs; 60/80/120/160 mg ER caps; 1 mg/mL IV (1) · 100 mg/mL vial for IV infusion (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 2.5, 5, 10, 20 mg tabs (2) · 2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) · 42 mg capsules (1) · 5 mg, 10 mg, 20 mg tablets (1) · 5, 10 mg tabs (1) · 50, 100, 200 mg tabs (1) · 7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) (1) · 70 mg/mL or 140 mg/mL prefilled autoinjector (1) · Dextromethorphan 45 mg + bupropion 105 mg ER tablets (1) · Dried leaves; absinthe liqueur (120–160 proof, with hyssop, lemon balm, fennel, anise, sometimes Acorus calamus) (1) · Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)

None (1) · 10 mg per 24 h (1) · 100 mg/d (ED); 20 mg TID (PAH) (1) · 140 mg/month (1) · 2 tablets/day (dextromethorphan 90 mg / bupropion 210 mg) (1) · 20 mg/d (3) · 20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH) (1) · 200 mg/d (1) · 200 mg/d (100 mg/d if on CYP3A4 inhibitors) (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 28/10 mg/d (1) · 300 mg/quarter (1) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) · 40 mg/d (3) · 400 mg/d (1) · 42 mg/d (1) · 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1) · 640 mg/d (HTN); 240 mg/d (migraine) (1) · 675 mg/quarter (1)

Intranasal (1) · Intravenous infusion (1) · IV (2) · IV (Revatio) (1) · Oral (17) · Oral (capsule whole or opened/sprinkled on applesauce) (1) · Subcutaneous (3)

None (1) · 1–2 h (2) · 1–2 h (PO), immediate (IV) (1) · 1–2 h (PO); immediate (IV) (1) · 30 min (1) · 30–60 min (1) · 30–90 min (1) · 4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism) (1) · Antipsychotic effect over weeks (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Component effects accumulate over weeks (1) · Effect demonstrated within 24 hours in some patients (1) · Onset of preventive effect over weeks; some patients respond after first dose (1) · Over weeks (2) · Pain relief reported within 15 min in trials (1) · Significant antidepressant response by week 1 in trials (faster than monoaminergic antidepressants which take 4-6 weeks) (1) · Typical antidepressant 4-6 week onset (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) · Weeks for psychosis/mood efficacy (1) · ~15 min (fastest of the PDE5 inhibitors) (1) · ~30 min (1)

None (1) · 24 h (3) · 3-month dosing interval (1) · 4–5 h (1) · 4–6 h (1) · 6–12 h (IR); 24 h (ER) (1) · 6–12 h (tartrate); 24 h (succinate) (1) · 6–8 h (1) · Daily dosing (4) · Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1) · Long (1) · Monthly dosing (2) · Monthly or quarterly dosing (1) · Sustained with twice-daily dosing (1) · Up to 36 h ("the weekend pill") (1) · ~4 h (1) · ~48 h sustained pain freedom in responders (1)

None (1) · 2–3 h (1) · 3–6 h (1) · 3–7 h (1) · 4–5 h (1) · 9–12 h (1) · Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) · Dextromethorphan ~22 h (when CYP2D6 inhibited); bupropion ~21 h (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~17.5 h (1) · ~18 hours (terminal) (1) · ~25 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~27 days (2) · ~28 days (1) · ~31 days (1) · ~4 h (1) · ~5 h (1) · ~6.6 h (1) · ~60–80 h (memantine); ~70 h (donepezil) (1) · ~66 hours (1) · ~91 hours (1)

None (1) · 100% (IV) (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Adequate oral bioavailability (1) · Limited but adequate; take with food (1) · Not formally characterized for the combination (1) · Not formally established (1) · Not formally established (high SC) (1) · Rapid absorption; absolute bioavailability not formally established (1) · Reasonable (not formally established as a percentage) (1) · ~100% both components (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~15% (extensive hepatic first-pass) (1) · ~25% (extensive hepatic first-pass) (1) · ~40% (1) · ~5% intranasal (1) · ~50% (1) · ~60% (1) · ~72% (with food); much lower fasting (~36%) (1) · ~75% (1) · ~82% SC (1) · ~90% (low first-pass) (1) · ~95% (1)

None (1) · Category B (3) · Category C (5) · Category C (not relevant; not used in women) (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data (1) · Limited data; avoid (6) · Limited data; National Pregnancy Registry available (1) · Limited data; National Pregnancy Registry for Atypical Antipsychotics (1) · Limited data; weigh benefits/risks (2) · Not relevant (geriatric problem) (1)

A

B

C

E

F

G

L

M

N

P

S

T

V

Z